Comparative Pharmacology
Head-to-head clinical analysis: HETRAZAN versus MINTEZOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HETRAZAN versus MINTEZOL.
HETRAZAN vs MINTEZOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diethylcarbamazine (HETRAZAN) sensitizes microfilariae to phagocytosis by immobilizing them and altering their surface, making them more susceptible to destruction by host immune cells. It also has anthelminthic activity against adult worms.
Thiabendazole inhibits the mitochondrial fumarate reductase system in susceptible helminths, disrupting energy metabolism.
2 mg/kg orally three times daily after meals for 3 weeks (total dose 120 mg/kg per course). Maximum single dose: 10 mg/kg.
50 mg/kg/day orally in 2-3 divided doses, maximum 3 g/day, for 2-3 days.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life: 2-8 hours (mean 4 hours). Hepatic impairment prolongs; dose adjustment recommended.
Renal excretion of unchanged drug accounts for approximately 50-60% of elimination; the remainder is metabolized hepatically with metabolites excreted in urine. Fecal elimination is minimal (<5%).
Renal: 90% within 24 hours (5% unchanged, 85% as metabolites). Fecal: <10%.
Category C
Category C
Anthelmintic
Anthelmintic